| Host |
Rabbit |
| Klon |
ZR365 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Testis |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human TFE3 protein |
| Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
7 ml |
Ready-to-use |
CE/IVD |
Z2605RP |
-
|
| Host |
Rabbit |
| Klon |
ZR365 |
| Format |
concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Testis |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human TFE3 protein |
| Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
0.5 ml |
concentrate |
CE/IVD |
Z2605RS |
-
|
| Host |
Rabbit |
| Klon |
ZR365 |
| Format |
concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Testis |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human TFE3 protein |
| Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
0.1 ml |
concentrate |
CE/IVD |
Z2605RT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM105 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
| Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
1 ml |
Concentrate |
CE/IVD |
Z2416ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM105 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
| Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
7 ml |
Ready-to-use |
CE/IVD |
Z2416MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM105 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
| Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
0.5 ml |
Concentrate |
CE/IVD |
Z2416MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM105 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
| Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
0.1 ml |
Concentrate |
CE/IVD |
Z2416MT |
-
|
| Host |
Mouse |
| Klon |
A6.1 |
| Format |
Concentrate |
| Methode |
F, P, IF, IP, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
1 ml |
Concentrate |
CE/IVD |
MOB315 |
-
|
| Host |
Mouse |
| Klon |
A6.1 |
| Format |
Concentrate |
| Methode |
F, P, IF, IP, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB315-01 |
-
|
| Host |
Mouse |
| Klon |
A6.1 |
| Format |
Concentrate |
| Methode |
F, P, IF, IP, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB315-05 |
-
|
| Host |
Rabbit |
| Klon |
SP112 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma, tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human TS |
| Lokalisation |
Cytoplasm, nucleus |
Thymidylate Synthase (TS)
|
Zytomed Systems GmbH |
SP112 |
1 ml |
Concentrate |
RUO |
520-4124 |
-
|
| Host |
Mouse |
| Klon |
TS106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
5-FU resistant cancer. |
| Verdünnung |
1:50 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human thymidylate synthase |
| Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
1 ml |
Concentrate |
CE/IVD |
Z2199ML |
-
|
| Host |
Mouse |
| Klon |
TS106 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
5-FU resistant cancer. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human thymidylate synthase |
| Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
7 ml |
Ready-to-use |
CE/IVD |
Z2199MP |
-
|
| Host |
Mouse |
| Klon |
TS106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
5-FU resistant cancer. |
| Verdünnung |
1:50 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human thymidylate synthase |
| Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
0.5 ml |
Concentrate |
CE/IVD |
Z2199MS |
-
|
| Host |
Mouse |
| Klon |
TS106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
5-FU resistant cancer. |
| Verdünnung |
1:50 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human thymidylate synthase |
| Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
0.1 ml |
Concentrate |
CE/IVD |
Z2199MT |
-
|
| Host |
Mouse |
| Klon |
1D4 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
1 ml |
Concentrate |
CE/IVD |
MOB223 |
-
|
| Host |
Mouse |
| Klon |
1D4 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB223-01 |
-
|
| Host |
Mouse |
| Klon |
1D4 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB223-05 |
-
|
| Host |
Mouse |
| Klon |
1D4 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Thyroid |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM576 |
-
|
| Host |
Mouse |
| Klon |
1D4 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Thyroid |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
25 ml |
Ready-to-use |
CE/IVD |
PDM576-25 |
-
|
| Host |
Mouse |
| Klon |
2H11+6E1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Thyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
Purified human thyroglobulin |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
1ml |
Concentrate |
CE/IVD |
Z2062ML |
-
|
| Host |
Mouse |
| Klon |
2H11+6E1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Thyroid. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
Purified human thyroglobulin |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2062MP |
-
|
| Host |
Mouse |
| Klon |
2H11+6E1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Thyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
Purified human thyroglobulin |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2062MS |
-
|
| Host |
Mouse |
| Klon |
2H11+6E1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Thyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
Purified human thyroglobulin |
| Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2062MT |
-
|
| Host |
Mouse |
| Klon |
MoAb47 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
1 ml |
Concentrate |
CE/IVD |
MOB418 |
-
|
| Host |
Mouse |
| Klon |
MoAb47 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.1 ml |
Concentrate |
CE/IVD |
MOB418-01 |
-
|
| Host |
Mouse |
| Klon |
MoAb47 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.5 ml |
Concentrate |
CE/IVD |
MOB418-05 |
-
|
| Host |
Mouse |
| Klon |
MoAb47 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thyroid |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
6 ml |
ready-to-use |
CE/IVD |
PDM418 |
-
|
| Host |
Rabbit |
| Klon |
SP141 |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
IHC-P |
| Vorbehandlung |
Citrate pH 6 |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
0.5 ml |
Concentrate |
RUO |
520-4412 |
-
|
| Host |
Rabbit |
| Klon |
SP141 |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
IHC-P |
| Vorbehandlung |
Citrate pH 6 |
| Positivkontrolle |
Thyroid |
| Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
1 ml |
Concentrate |
RUO |
520-4414 |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
7 ml |
Ready-to-use |
CE/IVD |
ALI130G7 |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
AVI130G |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.1 ml |
Concentrate |
CE/IVD |
CM130A |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.5 ml |
Concentrate |
CE/IVD |
CM130B |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
1 ml |
Concentrate |
CE/IVD |
CM130C |
-
|
| Host |
Mouse |
| Klon |
TIA-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
PM130AA |
-
|
| Host |
Mouse |
| Klon |
2G9A10F5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
| Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2183ML |
-
|
| Host |
Mouse |
| Klon |
2G9A10F5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
| Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2183MP |
-
|
| Host |
Mouse |
| Klon |
2G9A10F5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
| Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2183MS |
-
|
| Host |
Mouse |
| Klon |
2G9A10F5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
| Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2183MT |
-
|
| Host |
Rabbit |
| Klon |
ZR284 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Full-length of human TIA-1 protein |
| Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
1 ml |
Concentrate |
CE/IVD |
Z2599RL |
-
|
| Host |
Rabbit |
| Klon |
ZR284 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Full-length of human TIA-1 protein |
| Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
7 ml |
ready-to-use |
CE/IVD |
Z2599RP |
-
|
| Host |
Rabbit |
| Klon |
ZR284 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Full-length of human TIA-1 protein |
| Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
0.5 ml |
Concentrate |
CE/IVD |
Z2599RS |
-
|
| Host |
Rabbit |
| Klon |
ZR284 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Full-length of human TIA-1 protein |
| Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
0.1 ml |
Concentrate |
CE/IVD |
Z2599RT |
-
|
| Host |
Rabbit |
| Klon |
BLR047F |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
0.1 ml |
Concentrate |
CE/IVD |
ACI3243A |
-
|
| Host |
Rabbit |
| Klon |
BLR047F |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
1 ml |
Concentrate |
CE/IVD |
ACI3243C |
-
|
| Host |
Mouse |
| Klon |
BC41 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3254A |
-
|
| Host |
Mouse |
| Klon |
BC41 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
1 ml |
Concentrate |
CE/IVD |
ACI3254C |
-
|
| Host |
Rabbit |
| Klon |
BLR047F |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
6 ml |
Ready-to-use |
CE/IVD |
API3243AA |
-
|
| Host |
Mouse |
| Klon |
BC41 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
6 ml |
Ready-to-use |
CE/IVD |
API3254AA |
-
|